Literature DB >> 6167449

Enhancing the frequency of antigen-specific hybridomas.

P C Fox, E H Berenstein, R P Siraganian.   

Abstract

Techniques were developed to enhance the frequency of antigen-specific hybridomas by enriching for antibody precursor or-producing lymphocytes prior to cell fusion. Spleen cells of immunized animals were either (a) cultured in vitro for 3-4 days in the presence of the immunizing antigen or (b) adoptively transferred into X-irradiated syngeneic recipients followed immediately by an in vivo antigen boost 4 days prior to use in cell fusion. There was a 10-fold increase in the percentage of wells which develop antigen-specific, antibody-secreting hybridomas following these treatments. These techniques allow an increased yield of hybridomas with a greatly decreased technical effort.

Mesh:

Substances:

Year:  1981        PMID: 6167449     DOI: 10.1002/eji.1830110516

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  6 in total

1.  Monoclonal antibodies: a potentially powerful tool in the diagnosis and treatment of infectious diseases.

Authors:  G Spira; R R Pollock; A Bargellesi; M D Scharff
Journal:  Eur J Clin Microbiol       Date:  1985-06       Impact factor: 3.267

2.  Monoclonal antibodies against the antigen receptor on a cloned T-cell hybrid.

Authors:  L E Samelson; R N Germain; R H Schwartz
Journal:  Proc Natl Acad Sci U S A       Date:  1983-11       Impact factor: 11.205

Review 3.  Clinical laboratory applications of monoclonal antibodies.

Authors:  W J Payne; D L Marshall; R K Shockley; W J Martin
Journal:  Clin Microbiol Rev       Date:  1988-07       Impact factor: 26.132

4.  Depletion by monolayer binding of specific precursors of antibody-forming cells directed against cellular antigens.

Authors:  A D Nash; W Boyle
Journal:  Immunology       Date:  1986-03       Impact factor: 7.397

5.  Characterization of monoclonal antibodies to fimbria-associated adhesins of Bacteroides loescheii PK1295.

Authors:  E I Weiss; J London; P E Kolenbrander; R N Andersen; C Fischler; R P Siraganian
Journal:  Infect Immun       Date:  1988-01       Impact factor: 3.441

6.  Studies of lymphokine-activated killer (LAK) cells. I. Evidence using novel monoclonal antibodies that most human LAK precursor cells share a common surface marker.

Authors:  D G Morris; H F Pross
Journal:  J Exp Med       Date:  1989-03-01       Impact factor: 14.307

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.